BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30986499)

  • 1. Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation.
    Acevedo MJ; Wilder JS; Adams S; Davis J; Kelly C; Hilligoss D; Carroll E; Blacklock-Schuver B; Cole K; Kang EM; Hsu AP; Kanakry CG; Dimitrova D; Kanakry JA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1666-1673. PubMed ID: 30986499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matched versus Haploidentical Hematopoietic Stem Cell Transplantation as Treatment Options for Primary Immunodeficiencies in Children.
    Holzer U; Döring M; Eichholz T; Ebinger M; Queudeville M; Turkiewicz D; Schwarz K; Handgretinger R; Lang P; Toporski J
    Transplant Cell Ther; 2021 Jan; 27(1):71.e1-71.e12. PubMed ID: 32966882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
    Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
    Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
    Nakaya Y; Koh H; Konuma T; Shimomura Y; Ishiyama K; Itonaga H; Hino M; Doki N; Nishida T; Ohigashi H; Matsuoka KI; Kanda Y; Maruyama Y; Sawa M; Eto T; Hiramoto N; Fukuda T; Atsuta Y; Nakamae H
    Transplant Cell Ther; 2024 Mar; 30(3):316.e1-316.e12. PubMed ID: 38108263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!
    Kindwall-Keller TL; Ballen KK
    Oncologist; 2017 Sep; 22(9):1125-1134. PubMed ID: 28546462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
    Hong S; Rybicki L; Mclellan L; Dabney J; Gerds AT; Rotz SJ; Kalaycio M; Hanna R; Hamilton BK; Majhail NS; Sobecks RM
    Transplant Cell Ther; 2022 Apr; 28(4):217.e1-217.e6. PubMed ID: 35074556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.
    Bashey A; Solomon SR
    Bone Marrow Transplant; 2014 Aug; 49(8):999-1008. PubMed ID: 24842530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status.
    Konuma T; Yamasaki S; Ishiyama K; Mizuno S; Hayashi H; Uchida N; Shimabukuro M; Tanaka M; Kuriyama T; Onizuka M; Ishiwata K; Sawa M; Tanaka T; Ohigashi H; Fujiwara SI; Matsuoka KI; Ota S; Nishida T; Kanda Y; Fukuda T; Atsuta Y; Nakasone H; Yanada M;
    Transplant Cell Ther; 2024 Feb; 30(2):215.e1-215.e18. PubMed ID: 38081415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.
    Guru Murthy GS; Kim S; Hu ZH; Estrada-Merly N; Abid MB; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bredeson C; Cahn JY; Cerny J; Diaz Perez MA; Farhadfar N; Gale RP; Ganguly S; Gergis U; Hildebrandt GC; Grunwald MR; Hashmi S; Hossain NM; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Hamilton BK; Lazarus HM; Liesveld J; Litzow M; Marks DI; Murthy HS; Nathan S; Nazha A; Nishihori T; Patel SS; Pawarode A; Rizzieri D; Savani B; Seo S; Solh M; Ustun C; van der Poel M; Verdonck LF; Vij R; Wirk B; Oran B; Nakamura R; Scott B; Saber W
    JAMA Oncol; 2022 Mar; 8(3):404-411. PubMed ID: 35024768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiencies in Korea: Eleven-Year Experience in a Single Center.
    Yi ES; Choi YB; Lee NH; Lee JW; Sung KW; Koo HH; Kang ES; Kim YJ; Yoo KH
    J Clin Immunol; 2018 Oct; 38(7):757-766. PubMed ID: 30151618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
    Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34+ Stem Cell Selection and CD3+ T Cell Add-Back from Matched Unrelated Adult Donors in Children with Primary Immunodeficiencies and Hematological Diseases.
    Porta F; Comini M; Soncini E; Carracchia G; Maffeis M; Pintabona V; Bolda F; Beghin A; Schumacher RF; Lanfranchi A
    Transplant Cell Ther; 2021 May; 27(5):426.e1-426.e9. PubMed ID: 33965183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
    Al Hamed R; Ngoya M; Galimard JE; Sengeloev H; Gedde-Dahl T; Kulagin A; Platzbecker U; Yakoub-Agha I; Byrne JL; Valerius T; Socie G; Kröger N; Blaise D; Bazarbachi A; Sanz J; Ciceri F; Nagler A; Mohty M
    Cancer; 2023 Sep; 129(17):2645-2654. PubMed ID: 37269074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis.
    Ma L; Han X; Jiang S; Meng Q; Zhang L; Bao H
    Hematology; 2020 Dec; 25(1):356-365. PubMed ID: 33054609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.
    Auletta JJ; Kou J; Chen M; Bolon YT; Broglie L; Bupp C; Christianson D; Cusatis RN; Devine SM; Eapen M; Hamadani M; Hengen M; Lee SJ; Moskop A; Page KM; Pasquini MC; Perez WS; Phelan R; Riches ML; Rizzo JD; Saber W; Spellman SR; Stefanski HE; Steinert P; Tuschl E; Yusuf R; Zhang MJ; Shaw BE
    Transplant Cell Ther; 2023 Jun; 29(6):346.e1-346.e10. PubMed ID: 36924931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Maffini E; Labopin M; Kröger N; Finke J; Stelljes M; Schroeder T; Einsele H; Tischer J; Bornhäuser M; Bethge W; Brecht A; Rösler W; Dreger P; Schäfer-Eckart K; Passweg J; Blau IW; Nagler A; Ciceri F; Mohty M
    Bone Marrow Transplant; 2024 Mar; ():. PubMed ID: 38555412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.
    Bohannon L; Tang H; Page K; Ren Y; Jung SH; Artica A; Britt A; Islam P; Siamakpour-Reihani S; Giri V; Lew M; Kelly M; Choi T; Gasparetto C; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Horwitz M; Sung A
    Transplant Cell Ther; 2021 Aug; 27(8):669.e1-669.e8. PubMed ID: 33991725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
    Dreger P; Sureda A; Ahn KW; Eapen M; Litovich C; Finel H; Boumendil A; Gopal A; Herrera AF; Schmid C; Diez-Martin JL; Fuchs E; Bolaños-Meade J; Gooptu M; Al Malki MM; Castagna L; Ciurea SO; Dominietto A; Blaise D; Ciceri F; Tischer J; Corradini P; Montoto S; Robinson S; Gülbas Z; Hamadani M
    Blood Adv; 2019 Feb; 3(3):360-369. PubMed ID: 30723110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.